Kodiak Sciences Inc. (KOD)
Kodiak Sciences Inc. (KOD) Just Flashed Golden Cross Signal: Do You Buy?
Kodiak Sciences Inc. (KOD) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, KOD's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Kodiak Q3 Loss Narrower Than Expected, Pipeline Development in Focus
KOD reports a narrower-than-expected loss for the third quarter of 2024. The company provides updates regarding its pipeline development plans.
Kodiak Counts on Tarcocimab Eye Disease Program Despite Setbacks
KOD is evaluating tarcocimab in a phase III diabetic retinopathy study, which is set to form the basis for a regulatory filing across three eye disease indications.
Why Is Kodiak Sciences (KOD) Down 8.1% Since Last Earnings Report?
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?
Kodiak (KOD) Q2 Loss Narrower Than Expected, Pipeline in Focus
Kodiak (KOD) reports a narrower-than-expected loss for the second quarter of 2024. The company provides updates regarding its pipeline development plans.
All You Need to Know About Kodiak Sciences (KOD) Rating Upgrade to Buy
Kodiak Sciences (KOD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio?
Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications.
Why Is Kodiak Sciences (KOD) Down 26.2% Since Last Earnings Report?
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?
Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus
Kodiak (KOD) reports better-than-expected first-quarter 2024 results and provides updates regarding its pipeline development plans.
